Simone Vodret
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Simone Vodret has a total of 218 co-authors. Here are the top co-authors by number of shared publications:
- Serena Zacchigna
Cardiovascular Biology Laboratory, International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy
8 shared publications - Andrés Fernando Muro
International Centre for Genetic Engineering and Biotechnology (ICGEB), 34149 Trieste, Italy
7 shared publications - Mauro Giacca
King's College London
4 shared publications Alessandra Iaconcig
International Centre for Genetic Engineering and Biotechnology (ICGEB), Padriciano, 99, 34149 Trieste, Italy
3 shared publicationsAndrea Colliva
Cardiovascular Biology Laboratory, International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy
3 shared publications- Gianluca Lorenzo Perrucci
Centro Cardiologico Monzino IRCCS 1 Unit of Cardio-Oncology and Vascular Biology Milan
3 shared publications
Latest Publications
- Open Access
- 11 November 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (12)
Cilengitide limits syndromic and sporadic thoracic aortic aneurysm by targeting specific αV integrin
Thoracic aortic aneurysm (TAA) is one of the major causes of morbidity and mortality worldwide, still lacking an etiologic therapy. Aberrant activation of TGF-β and dysregulation of mechanotransduction signalling in vascular smooth muscle cells (VSMCs) play a key role in the pathology. However, a precise picture of molecular mechanisms in the disease is still unclear. Integrins containing the αV subunit are central in pro-fibrotic pathways mediated by TGF-β and mechanotransduction signalling pathways, but their role as a potential therapeutic target in syndromic and sporadic TAAs still needs investigation. We showed higher expression levels of αV integrin in both types of human TAAs and that the αV integrin inhibitor Cilengitide limits pro-fibrotic events in patient-derived VSMCs. In vivo results defined Cilengitide as the most effective and promising drug for the treatment of TAAs in humans.
- 11 November 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (12)
Open AccessCilengitide limits syndromic and sporadic thoracic aortic aneurysm by targeting specific αV integrin
Thoracic aortic aneurysm (TAA) is one of the major causes of morbidity and mortality worldwide, still lacking an etiologic therapy. Aberrant activation of TGF-β and dysregulation of mechanotransduction signalling in vascular smooth muscle cells (VSMCs) play a key role in the pathology. However, a precise picture of molecular mechanisms in the disease is still unclear. Integrins containing the αV subunit are central in pro-fibrotic pathways mediated by TGF-β and mechanotransduction signalling pathways, but their role as a potential therapeutic target in syndromic and sporadic TAAs still needs investigation. We showed higher expression levels of αV integrin in both types of human TAAs and that the αV integrin inhibitor Cilengitide limits pro-fibrotic events in patient-derived VSMCs. In vivo results defined Cilengitide as the most effective and promising drug for the treatment of TAAs in humans.
- Top Cited Papers
- 23 April 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 392 (6796) , eads9412
Mechanical load inhibits cancer growth in mouse and human hearts
The heart rarely develops cancer, and, at the same time, it lacks regenerative capacity, as cardiomyocytes stop proliferating after birth. This suggests that mechanisms limiting cardiac regeneration may also protect against cancer. In this work, we investigated the role of mechanical load and used in vivo cancer models and ex vivo engineered heart tissues to show that mechanical load reduces cancer cell proliferation in the myocardium. Spatial transcriptomics of human cardiac metastases revealed decreased histone methylation and chromatin compaction. These changes affect chromatin accessibility at proliferation-related loci, with Nesprin-2 identified as a key mechanosensor. Our results uncover how mechanical forces protect the heart from cancer and suggest potential strategies for cancer therapy based on mechanical stimulation.
- 23 April 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 392 (6796) , eads9412
Top Cited PapersMechanical load inhibits cancer growth in mouse and human hearts
The heart rarely develops cancer, and, at the same time, it lacks regenerative capacity, as cardiomyocytes stop proliferating after birth. This suggests that mechanisms limiting cardiac regeneration may also protect against cancer. In this work, we investigated the role of mechanical load and used in vivo cancer models and ex vivo engineered heart tissues to show that mechanical load reduces cancer cell proliferation in the myocardium. Spatial transcriptomics of human cardiac metastases revealed decreased histone methylation and chromatin compaction. These changes affect chromatin accessibility at proliferation-related loci, with Nesprin-2 identified as a key mechanosensor. Our results uncover how mechanical forces protect the heart from cancer and suggest potential strategies for cancer therapy based on mechanical stimulation.
- Open Access
Cilengitide limits the progression of both syndromic and sporadic thoracic aortic aneurysms by targeting alpha V integrins
Thoracic aortic aneurysm is a life-threatening condition due to either genetic syndromes ( e.g. , Marfan syndrome) or cardiovascular risk factors ( e.g. , hypertension, aging and smoking), which favour the onset of sporadic thoracic aneurysms. Activation of the transforming growth factor-β pathway and dysregulation of mechanotransduction signals in vascular smooth muscle cells play a key role in the development of both syndromic and sporadic forms of thoracic aortic aneurysm. The precise molecular mechanisms underlying thoracic aortic aneurysm onset and progression are still unresolved and available therapies merely rely on surgical intervention. Integrins containing the αV subunit are central to both transforming growth factor-β (TGF-β) and mechanotransduction signalling pathways, leading to pro-fibrotic molecular events. Here we investigate the role of αV integrins in the development of both syndromic and sporadic thoracic aortic aneurysms and the therapeutic potential of two αV integrin inhibitors (Cilengitide and GLPG0187). We observed that αV integrins are more expressed in both types of human thoracic aortic aneurysms and that integrin inhibition limits TGF-β activation and mechanotransduction-related pro-fibrotic pathways in patient-derived vascular smooth muscle cells. In vivo experiments revealed that Cilengitide is the most effective αV integrin inhibitor in limiting the dilation of the aortic bulb in murine models of both syndromic and sporadic forms of thoracic aortic aneurysms. These findings set the αV integrin inhibitor Cilengitide as a promising drug for the treatment of thoracic aortic aneurysms.
Open AccessCilengitide limits the progression of both syndromic and sporadic thoracic aortic aneurysms by targeting alpha V integrins
Thoracic aortic aneurysm is a life-threatening condition due to either genetic syndromes ( e.g. , Marfan syndrome) or cardiovascular risk factors ( e.g. , hypertension, aging and smoking), which favour the onset of sporadic thoracic aneurysms. Activation of the transforming growth factor-β pathway and dysregulation of mechanotransduction signals in vascular smooth muscle cells play a key role in the development of both syndromic and sporadic forms of thoracic aortic aneurysm. The precise molecular mechanisms underlying thoracic aortic aneurysm onset and progression are still unresolved and available therapies merely rely on surgical intervention. Integrins containing the αV subunit are central to both transforming growth factor-β (TGF-β) and mechanotransduction signalling pathways, leading to pro-fibrotic molecular events. Here we investigate the role of αV integrins in the development of both syndromic and sporadic thoracic aortic aneurysms and the therapeutic potential of two αV integrin inhibitors (Cilengitide and GLPG0187). We observed that αV integrins are more expressed in both types of human thoracic aortic aneurysms and that integrin inhibition limits TGF-β activation and mechanotransduction-related pro-fibrotic pathways in patient-derived vascular smooth muscle cells. In vivo experiments revealed that Cilengitide is the most effective αV integrin inhibitor in limiting the dilation of the aortic bulb in murine models of both syndromic and sporadic forms of thoracic aortic aneurysms. These findings set the αV integrin inhibitor Cilengitide as a promising drug for the treatment of thoracic aortic aneurysms.
- Open Access
- 28 February 2025
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 185, 117946
Anti-miRNA therapeutics for uterine fibroids
- 28 February 2025
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 185, 117946
Open AccessAnti-miRNA therapeutics for uterine fibroids
- Open Access
- 23 March 2022
- Published by Elsevier in Translational Oncology
- Vol. 20, 101400
Force-feeding malignant mesothelioma stem-cell like with exosome-delivered miR-126 induces tumour cell killing
- 23 March 2022
- Published by Elsevier in Translational Oncology
- Vol. 20, 101400
Open AccessForce-feeding malignant mesothelioma stem-cell like with exosome-delivered miR-126 induces tumour cell killing
- Top Cited Papers
- 4 May 2020
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 117 (1) , 43-59
Towards standardization of echocardiography for the evaluation of left ventricular function in adult rodents: a position paper of the ESC Working Group on Myocardial Function
Echocardiography is a reliable and reproducible method to assess non-invasively cardiac function in clinical and experimental research. Significant progress in the development of echocardiographic equipment and transducers has led to the successful translation of this methodology from humans to rodents, allowing for the scoring of disease severity and progression, testing of new drugs, and monitoring cardiac function in genetically modified or pharmacologically treated animals. However, as yet, there is no standardization in the procedure to acquire echocardiographic measurements in small animals. This position paper focuses on the appropriate acquisition and analysis of echocardiographic parameters in adult mice and rats, and provides reference values, representative images, and videos for the accurate and reproducible quantification of left ventricular function in healthy and pathological conditions.
- 4 May 2020
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 117 (1) , 43-59
Top Cited PapersTowards standardization of echocardiography for the evaluation of left ventricular function in adult rodents: a position paper of the ESC Working Group on Myocardial Function
Echocardiography is a reliable and reproducible method to assess non-invasively cardiac function in clinical and experimental research. Significant progress in the development of echocardiographic equipment and transducers has led to the successful translation of this methodology from humans to rodents, allowing for the scoring of disease severity and progression, testing of new drugs, and monitoring cardiac function in genetically modified or pharmacologically treated animals. However, as yet, there is no standardization in the procedure to acquire echocardiographic measurements in small animals. This position paper focuses on the appropriate acquisition and analysis of echocardiographic parameters in adult mice and rats, and provides reference values, representative images, and videos for the accurate and reproducible quantification of left ventricular function in healthy and pathological conditions.
- Open Access
- 1 January 2020
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 117 (1) , 256-270
Genetic lineage tracing reveals poor angiogenic potential of cardiac endothelial cells
Aims: Cardiac ischaemia does not elicit an efficient angiogenic response. Indeed, lack of surgical revascularization upon myocardial infarction results in cardiomyocyte death, scarring, and loss of contractile function. Clinical trials aimed at inducing therapeutic revascularization through the delivery of pro-angiogenic molecules after cardiac ischaemia have invariably failed, suggesting that endothelial cells in the heart cannot mount an efficient angiogenic response. To understand why the heart is a poorly angiogenic environment, here we compare the angiogenic response of the cardiac and skeletal muscle using a lineage tracing approach to genetically label sprouting endothelial cells. Methods and results: We observed that overexpression of the vascular endothelial growth factor in the skeletal muscle potently stimulated angiogenesis, resulting in the formation of a massive number of new capillaries and arterioles. In contrast, response to the same dose of the same factor in the heart was blunted and consisted in a modest increase in the number of new arterioles. By using Apelin-CreER mice to genetically label sprouting endothelial cells we observed that different pro-angiogenic stimuli activated Apelin expression in both muscle types to a similar extent, however, only in the skeletal muscle, these cells were able to sprout, form elongated vascular tubes activating Notch signalling, and became incorporated into arteries. In the heart, Apelin-positive cells transiently persisted and failed to give rise to new vessels. When we implanted cancer cells in different organs, the abortive angiogenic response in the heart resulted in a reduced expansion of the tumour mass. Conclusion: Our genetic lineage tracing indicates that cardiac endothelial cells activate Apelin expression in response to pro-angiogenic stimuli but, different from those of the skeletal muscle, fail to proliferate and form mature and structured vessels. The poor angiogenic potential of the heart is associated with reduced tumour angiogenesis and growth of cancer cells.
- 1 January 2020
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 117 (1) , 256-270
Open AccessGenetic lineage tracing reveals poor angiogenic potential of cardiac endothelial cells
Aims: Cardiac ischaemia does not elicit an efficient angiogenic response. Indeed, lack of surgical revascularization upon myocardial infarction results in cardiomyocyte death, scarring, and loss of contractile function. Clinical trials aimed at inducing therapeutic revascularization through the delivery of pro-angiogenic molecules after cardiac ischaemia have invariably failed, suggesting that endothelial cells in the heart cannot mount an efficient angiogenic response. To understand why the heart is a poorly angiogenic environment, here we compare the angiogenic response of the cardiac and skeletal muscle using a lineage tracing approach to genetically label sprouting endothelial cells. Methods and results: We observed that overexpression of the vascular endothelial growth factor in the skeletal muscle potently stimulated angiogenesis, resulting in the formation of a massive number of new capillaries and arterioles. In contrast, response to the same dose of the same factor in the heart was blunted and consisted in a modest increase in the number of new arterioles. By using Apelin-CreER mice to genetically label sprouting endothelial cells we observed that different pro-angiogenic stimuli activated Apelin expression in both muscle types to a similar extent, however, only in the skeletal muscle, these cells were able to sprout, form elongated vascular tubes activating Notch signalling, and became incorporated into arteries. In the heart, Apelin-positive cells transiently persisted and failed to give rise to new vessels. When we implanted cancer cells in different organs, the abortive angiogenic response in the heart resulted in a reduced expansion of the tumour mass. Conclusion: Our genetic lineage tracing indicates that cardiac endothelial cells activate Apelin expression in response to pro-angiogenic stimuli but, different from those of the skeletal muscle, fail to proliferate and form mature and structured vessels. The poor angiogenic potential of the heart is associated with reduced tumour angiogenesis and growth of cancer cells.
- Open Access
- 9 October 2019
- Published by Springer Nature in npj Biofilms and Microbiomes
- Vol. 5 (1) , 1-11
Blue laser light inhibits biofilm formation in vitro and in vivo by inducing oxidative stress
Resolution of bacterial infections is often hampered by both resistance to conventional antibiotic therapy and hiding of bacterial cells inside biofilms, warranting the development of innovative therapeutic strategies. Here, we report the efficacy of blue laser light in eradicating Pseudomonas aeruginosa cells, grown in planktonic state, agar plates and mature biofilms, both in vitro and in vivo, with minimal toxicity to mammalian cells and tissues. Results obtained using knock-out mutants point to oxidative stress as a relevant mechanism by which blue laser light exerts its anti-microbial effect. Finally, the therapeutic potential is confirmed in a mouse model of skin wound infection. Collectively, these data set blue laser phototherapy as an innovative approach to inhibit bacterial growth and biofilm formation, and thus as a realistic treatment option for superinfected wounds.
- 9 October 2019
- Published by Springer Nature in npj Biofilms and Microbiomes
- Vol. 5 (1) , 1-11
Open AccessBlue laser light inhibits biofilm formation in vitro and in vivo by inducing oxidative stress
Resolution of bacterial infections is often hampered by both resistance to conventional antibiotic therapy and hiding of bacterial cells inside biofilms, warranting the development of innovative therapeutic strategies. Here, we report the efficacy of blue laser light in eradicating Pseudomonas aeruginosa cells, grown in planktonic state, agar plates and mature biofilms, both in vitro and in vivo, with minimal toxicity to mammalian cells and tissues. Results obtained using knock-out mutants point to oxidative stress as a relevant mechanism by which blue laser light exerts its anti-microbial effect. Finally, the therapeutic potential is confirmed in a mouse model of skin wound infection. Collectively, these data set blue laser phototherapy as an innovative approach to inhibit bacterial growth and biofilm formation, and thus as a realistic treatment option for superinfected wounds.
- Open Access
- 1 October 2019
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 5 (4)
miR-200 family members reduce senescence and restore idiopathic pulmonary fibrosis type II alveolar epithelial cell transdifferentiation
Rationale Alveolar type II (ATII) cells act as adult stem cells contributing to alveolar type I (ATI) cell renewal and play a major role in idiopathic pulmonary fibrosis (IPF), as supported by familial cases harbouring mutations in genes specifically expressed by these cells. During IPF, ATII cells lose their regenerative potential and aberrantly express pathways contributing to epithelial–mesenchymal transition (EMT). The microRNA miR-200 family is downregulated in IPF, but its effect on human IPF ATII cells remains unproven. We wanted to 1) evaluate the characteristics and transdifferentiating ability of IPF ATII cells, and 2) test whether miR-200 family members can rescue the regenerative potential of fibrotic ATII cells. Methods ATII cells were isolated from control or IPF lungs and cultured in conditions promoting their transdifferentiation into ATI cells. Cells were either phenotypically monitored over time or transfected with miR-200 family members to evaluate the microRNA effect on the expression of transdifferentiation, senescence and EMT markers. Results IPF ATII cells show a senescent phenotype (p16 and p21), overexpression of EMT (ZEB1/2) and impaired expression of ATI cell markers (AQP5 and HOPX) after 6 days of culture in differentiating medium. Transfection with certain miR-200 family members (particularly miR-200b-3p and miR-200c-3p) reduced senescence marker expression and restored the ability to transdifferentiate into ATI cells. Conclusions We demonstrated that ATII cells from IPF patients express senescence and EMT markers, and display a reduced ability to transdifferentiate into ATI cells. Transfection with certain miR-200 family members rescues this phenotype, reducing senescence and restoring transdifferentiation marker expression. Idiopathic pulmonary fibrosis alveolar epithelial type II cells show senescence and EMT features, but miR-200b and miR-200c can restore the ability of type II cells to transdifferentiate in vitro into type I alveolar epithelial cellshttp://bit.ly/359tlit
- 1 October 2019
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 5 (4)
Open AccessmiR-200 family members reduce senescence and restore idiopathic pulmonary fibrosis type II alveolar epithelial cell transdifferentiation
Rationale Alveolar type II (ATII) cells act as adult stem cells contributing to alveolar type I (ATI) cell renewal and play a major role in idiopathic pulmonary fibrosis (IPF), as supported by familial cases harbouring mutations in genes specifically expressed by these cells. During IPF, ATII cells lose their regenerative potential and aberrantly express pathways contributing to epithelial–mesenchymal transition (EMT). The microRNA miR-200 family is downregulated in IPF, but its effect on human IPF ATII cells remains unproven. We wanted to 1) evaluate the characteristics and transdifferentiating ability of IPF ATII cells, and 2) test whether miR-200 family members can rescue the regenerative potential of fibrotic ATII cells. Methods ATII cells were isolated from control or IPF lungs and cultured in conditions promoting their transdifferentiation into ATI cells. Cells were either phenotypically monitored over time or transfected with miR-200 family members to evaluate the microRNA effect on the expression of transdifferentiation, senescence and EMT markers. Results IPF ATII cells show a senescent phenotype (p16 and p21), overexpression of EMT (ZEB1/2) and impaired expression of ATI cell markers (AQP5 and HOPX) after 6 days of culture in differentiating medium. Transfection with certain miR-200 family members (particularly miR-200b-3p and miR-200c-3p) reduced senescence marker expression and restored the ability to transdifferentiate into ATI cells. Conclusions We demonstrated that ATII cells from IPF patients express senescence and EMT markers, and display a reduced ability to transdifferentiate into ATI cells. Transfection with certain miR-200 family members rescues this phenotype, reducing senescence and restoring transdifferentiation marker expression. Idiopathic pulmonary fibrosis alveolar epithelial type II cells show senescence and EMT features, but miR-200b and miR-200c can restore the ability of type II cells to transdifferentiate in vitro into type I alveolar epithelial cellshttp://bit.ly/359tlit
- Open Access
- 18 April 2019
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 4 (8)
High-throughput screening discovers antifibrotic properties of haloperidol by hindering myofibroblast activation
Fibrosis is a hallmark in the pathogenesis of various diseases, with very limited therapeutic solutions. A key event in the fibrotic process is the expression of contractile proteins, including α-smooth muscle actin (αSMA) by fibroblasts, which become myofibroblasts. Here, we report the results of a high-throughput screening of a library of approved drugs that led to the discovery of haloperidol, a common antipsychotic drug, as a potent inhibitor of myofibroblast activation. We show that haloperidol exerts its antifibrotic effect on primary murine and human fibroblasts by binding to sigma receptor 1, independent from the canonical transforming growth factor-β signaling pathway. Its mechanism of action involves the modulation of intracellular calcium, with moderate induction of endoplasmic reticulum stress response, which in turn abrogates Notch1 signaling and the consequent expression of its targets, including αSMA. Importantly, haloperidol also reduced the fibrotic burden in 3 different animal models of lung, cardiac, and tumor-associated fibrosis, thus supporting the repurposing of this drug for the treatment of fibrotic conditions.
- 18 April 2019
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 4 (8)
Open AccessHigh-throughput screening discovers antifibrotic properties of haloperidol by hindering myofibroblast activation
Fibrosis is a hallmark in the pathogenesis of various diseases, with very limited therapeutic solutions. A key event in the fibrotic process is the expression of contractile proteins, including α-smooth muscle actin (αSMA) by fibroblasts, which become myofibroblasts. Here, we report the results of a high-throughput screening of a library of approved drugs that led to the discovery of haloperidol, a common antipsychotic drug, as a potent inhibitor of myofibroblast activation. We show that haloperidol exerts its antifibrotic effect on primary murine and human fibroblasts by binding to sigma receptor 1, independent from the canonical transforming growth factor-β signaling pathway. Its mechanism of action involves the modulation of intracellular calcium, with moderate induction of endoplasmic reticulum stress response, which in turn abrogates Notch1 signaling and the consequent expression of its targets, including αSMA. Importantly, haloperidol also reduced the fibrotic burden in 3 different animal models of lung, cardiac, and tumor-associated fibrosis, thus supporting the repurposing of this drug for the treatment of fibrotic conditions.